Patents are not scientific and technological achievements and cannot be bought for direct production. It is a theory that has not been tested by production practice. Therefore, the purchase of pharmaceutical patents is not like the purchase of scientific and technological achievements, and it needs to be tested to determine whether it can be mass-produced.
If an enterprise buys a drug patent and wants to produce a product, the product produced must be different from the patent content. Therefore, when purchasing drug patents, enterprises should not forget to work out the acceptance criteria after the product is completed with the patentee. Because only products that meet national standards are qualified products, they can flow into the market and trade. Therefore, at the beginning of drug patent purchase, the technical performance standard of the product must be clearly written in the contract.
Patent is only a technical scheme, so it needs a transformation process, and this transformation process cannot be separated from the inventor's guidance. Therefore, it must be stated in the contract that the patent inventor should assist in production.
The conversion rate of drug patents in China is not high. There are many reasons for this situation, and researchers are not clear about the market demand; Enterprises don't know how to innovate and so on.